England and Germany ‘neck-and-neck’ in coronavirus vaccine race
Teams at Oxford University and BioNTech are competing to produce the first internationally accepted vaccination for Covid-19

The life-and-death sprint to find a drug that can protect us all from Covid-19 is a contest in which there ought to be no losers.
Yet the unprecedented efforts of the world’s scientists and drug companies to create a coronavirus vaccine have culminated in a familiar rivalry, says The Telegraph - “a playoff between teams in England and Germany”.
The first internationally licensed vaccine is expected to emerge either from Oxford University, in partnership with the Anglo-Swedish pharmaceutical company Astra-Zeneca, or from Germany’s BioNTech and its US-based manufacturing partner Pfizer.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
“Both products have completed successful phase one and two trials, with data suggesting they produced a ‘robust’ immune response - antibodies and T-cells - in volunteers after two doses,” the newspaper reports.
Scores of other potential vaccines are also under development, and in an unconventional move, two have been approved for use in their home countries before undergoing large-scale phase three trials.
Russia is planning to start mass vaccinations in October using a drug created by the Moscow-based Gameleya laboratory, while China will give soldiers a vaccine developed by medical lab CanSino and military researchers.
However, neither the Russian nor Chinese vaccine is likely to gain international acceptance without phase-three clinical trial results to reassure public health officials.
“Russia has released no scientific data as to the safety and effectiveness of its vaccine,” says CNBC.
By contrast, phase three trials of both the BioNTech and Oxford vaccines are well under way, and data from earlier testing has already been published.
“AstraZeneca has indicated they might be able to start delivering emergency vaccines as early as October, depending on the outcome of the studies,” says The New York Times. “Their phase one/two trial revealed that the vaccine was safe, causing no severe side effects.”
Although the German vaccine caused some “moderate side effects such as sleep disturbances and sore arms”, the paper adds, the drug also produced an effective immune response.
Both vaccines are likely to require two doses, according to The Telegraph, and “how long any protective effect will last” remains “unclear”.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Holden Frith is The Week’s digital director. He also makes regular appearances on “The Week Unwrapped”, speaking about subjects as diverse as vaccine development and bionic bomb-sniffing locusts. He joined The Week in 2013, spending five years editing the magazine’s website. Before that, he was deputy digital editor at The Sunday Times. He has also been TheTimes.co.uk’s technology editor and the launch editor of Wired magazine’s UK website. Holden has worked in journalism for nearly two decades, having started his professional career while completing an English literature degree at Cambridge University. He followed that with a master’s degree in journalism from Northwestern University in Chicago. A keen photographer, he also writes travel features whenever he gets the chance.
-
America's favorite fast food restaurants
The Explainer There are different ways of thinking about how Americans define how they most like to spend their money on burgers, tacos and fried chicken
-
Law: The battle over birthright citizenship
Feature Trump shifts his focus to nationwide injunctions after federal judges block his attempt to end birthright citizenship
-
The threat to the NIH
Feature The Trump administration plans drastic cuts to medical research. What are the ramifications?
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
RFK Jr.: A new plan for sabotaging vaccines
Feature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'
-
Unraveling autism: RFK Jr.'s vow to find a root cause
Feature RFK Jr. has vowed to find the root cause of the 'autism epidemic' in months. Scientists have doubts.
-
The sneaking rise of whooping cough
Under the Radar The measles outbreak isn't the only one to worry about
-
Five years on: How Covid changed everything
Feature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter